公开(公告)号：WO2018100558A8

公开(公告)日：2018-06-07

申请号：PCT/IB2017/057588

申请日：2017-12-01

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： YOSHIKAWA, Masato ,  SAITOH, Morihisa ,  KATO, Taisuke ,  YOSHITOMI, Yayoi ,  SEKI, Tomohiro ,  NAKAGAWA, Yasuo ,  TOMINARI, Yusuke ,  SETO, Masaki ,  SASAKI, Yusuke ,  OKANIWA, Masanori ,  ODA, Tsuneo ,  SHIBUYA, Akito ,  HIDAKA, Kosuke ,  SHIOKAWA, Zenyu ,  MURATA, Shumpei ,  OKABE, Atsutoshi ,  NAKADA, Yoshihisa ,  MOCHIZUKI, Michiyo ,  FREEZE, Brian Scott ,  TAWARAISHI, Taisuke ,  WADA, Yasufumi ,  GREENSPAN, Paul D.

IPC: C07H21/00 ,  C07H21/02 ,  A61K31/7084 ,  A61P35/00

Abstract: The present disclosure provides a compound having a STING (stimulator of interferon genes) agonistic activity, which may be expected to be useful as an agent for the prophylaxis or treatment of STING-related diseases, such as cancer. The present disclosure relates to a compound represented by the formula (I) wherein each symbol is as defined in the description, or a salt thereof.

公开(公告)号：WO2018100558A2

公开(公告)日：2018-06-07

申请号：PCT/IB2017/057588

申请日：2017-12-01

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： YOSHIKAWA, Masato ,  SAITOH, Morihisa ,  KATO, Taisuke ,  YOSHITOMI, Yayoi ,  SEKI, Tomohiro ,  NAKAGAWA, Yasuo ,  TOMINARI, Yusuke ,  SETO, Masaki ,  SASAKI, Yusuke ,  OKANIWA, Masanori ,  ODA, Tsuneo ,  SHIBUYA, Akito ,  HIDAKA, Kosuke ,  SHIOKAWA, Zenyu ,  MURATA, Shumpei ,  OKABE, Atsutoshi ,  NAKADA, Yoshihisa ,  MOCHIZUKI, Michiyo ,  FREEZE, Brian Scott ,  TAWARAISHI, Taisuke ,  WADA, Yasufumi ,  GREENSPAN, Paul D.

IPC: C07H21/00 ,  C07H21/02 ,  A61K31/7084 ,  A61P35/00

CPC classification number: C07H21/02 ,  A61P35/00 ,  C07H21/00

Abstract: The present disclosure provides a compound having a STING agonistic activity, which may be expected to be useful as an agent for the prophylaxis or treatment of STING-related diseases. The present disclosure relates to a compound represented by the formula (I), wherein each symbol is as defined in the description, or a salt thereof.

公开(公告)号：WO2012020848A1

公开(公告)日：2012-02-16

申请号：PCT/JP2011/068497

申请日：2011-08-09

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED ,  KORI, Masakuni ,  IMAEDA, Toshihiro ,  NAKAMURA, Shinji ,  TOYOFUKU, Masashi ,  HONDA, Eiji ,  ASANO, Yasutomi ,  UJIKAWA, Osamu ,  MOCHIZUKI, Michiyo

Inventor： KORI, Masakuni ,  IMAEDA, Toshihiro ,  NAKAMURA, Shinji ,  TOYOFUKU, Masashi ,  HONDA, Eiji ,  ASANO, Yasutomi ,  UJIKAWA, Osamu ,  MOCHIZUKI, Michiyo

IPC: C07D513/04 ,  A61K31/542 ,  A61P25/00

CPC classification number: C07D513/04

Abstract: Provided is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, which has an AMPA ( -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and the like.

Abstract translation: 提供由式（I）表示的化合物：其中每个符号如说明书中所定义，或其盐，其具有AMPA（ - 氨基-3-羟基-5-甲基-4-异恶唑丙酸）受体增强剂 行动。 本发明的化合物可用作抑郁症，精神分裂症，阿尔茨海默病或注意缺陷多动障碍（ADHD）等的预防或治疗药物。

公开(公告)号：WO2009093747A1

公开(公告)日：2009-07-30

申请号：PCT/JP2009/051299

申请日：2009-01-21

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED ,  ASO, Kazuyoshi ,  KOBAYASHI, Katsumi ,  TAKAI, Takafumi ,  KOJIMA, Takuto ,  TOKUMARU, Kazuyuki ,  MOCHIZUKI, Michiyo ,  HOASHI, Yasutaka

Inventor： ASO, Kazuyoshi ,  KOBAYASHI, Katsumi ,  TAKAI, Takafumi ,  KOJIMA, Takuto ,  TOKUMARU, Kazuyuki ,  MOCHIZUKI, Michiyo ,  HOASHI, Yasutaka

IPC: C07D487/04 ,  C07D498/04 ,  A61K31/4188 ,  A61P25/24 ,  A61P25/22

CPC classification number: C07D487/04 ,  A61K31/4188 ,  A61K31/519 ,  C07D239/70 ,  C07D498/04

Abstract: There is provided a compound of the formula (I') : wherein X is a nitrogen or CRx, Rx is a hydrogen, etc., R 1 is an optionally substituted hydrocarbon group, etc., R 2 is an optionally substituted hydrocarbon group, etc., ring A is 5- to -8-membered heterocyclic ring, etc., and each of Y 1 ,. Y 2 and Y 3 is an optionally substituted carbon or a nitrogen, etc.; or 'a salt thereof or a prodrug thereof., which have CRF receptor antagonistic activity and use thereof.

Abstract translation: 提供式（I'）的化合物：其中X是氮或CR x，Rx是氢等，R 1是任选取代的烃基等，R 2是任选取代的烃基等。 环A为5-至8-元杂环等，各为Y 1， Y2和Y3是任选取代的碳或氮等; 或其具有CRF受体拮抗活性的其盐或其前药，及其用途。

公开(公告)号：WO2008051533A2

公开(公告)日：2008-05-02

申请号：PCT/US2007/022472

申请日：2007-10-24

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED ,  ASO, Kazuyoshi ,  MOCHIZUKI, Michiyo ,  KOJIMA, Takuto ,  KOBAYASHI, Katsumi ,  PRATT, Scott, Alan ,  GYORKOS, Albert, Charles ,  CORRETTE, Christopher, Peter ,  CHO, Suk, Young

Inventor： ASO, Kazuyoshi ,  MOCHIZUKI, Michiyo ,  KOJIMA, Takuto ,  KOBAYASHI, Katsumi ,  PRATT, Scott, Alan ,  GYORKOS, Albert, Charles ,  CORRETTE, Christopher, Peter ,  CHO, Suk, Young

IPC: A61K31/4439

CPC classification number: C07D235/26 ,  C07D235/30 ,  C07D401/12 ,  C07D403/12

Abstract: There is provided a compound of the formula (1) wherein R 1 is an optionally substituted C 1-10 alkyl; R 2 is H, or a C 1-6 alkyl which may be substituted with 1 to 3 substituents; R 3 is a 5- or 6-membered aromatic group which may be substituted with 1 to 5 substituents, wherein the 5- or 6-membered aromatic group may be fused with a 5- or 6- membered ring which may be substituted with 1 to 3 C 1-6 alkyls; R 4 is a hydrogen, a halogen, a hydroxy, a cyano, a C 1-6 alkyl or a C 1-6 alkoxy; Z is -O-, -S-, -SO-, -SO 2 -, or - NR 5 - wherein R 5 is a hydrogen or a C 1-6 alkyl; or a salt thereof or a prodrug thereof, which have CRF receptor antagonist activity and use thereof.

Abstract translation: 本发明提供了式（1）的化合物，其中R 1是任选取代的C 1-10烷基; R 2是H或可以被1至3个取代基取代的C 1-6烷基; R 3是可以被1至5个取代基取代的5或6元芳族基团，其中5或6元芳族基团可以与5或6元环 可以被1至3个C 1-6烷基取代的环; R 4是氢，卤素，羟基，氰基，C 1-6烷基或C 1-6烷氧基; Z是-O - ， - S - ， - SO - ， - SO 2 - 或-NR 5 - ，其中R 5是 氢或C 1-6烷基; 或其盐或其前药，其具有CRF受体拮抗剂活性及其用途。

公开(公告)号：WO2018100558A9

公开(公告)日：2018-06-07

申请号：PCT/IB2017/057588

申请日：2017-12-01

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： YOSHIKAWA, Masato ,  SAITOH, Morihisa ,  KATO, Taisuke ,  YOSHITOMI, Yayoi ,  SEKI, Tomohiro ,  NAKAGAWA, Yasuo ,  TOMINARI, Yusuke ,  SETO, Masaki ,  SASAKI, Yusuke ,  OKANIWA, Masanori ,  ODA, Tsuneo ,  SHIBUYA, Akito ,  HIDAKA, Kosuke ,  SHIOKAWA, Zenyu ,  MURATA, Shumpei ,  OKABE, Atsutoshi ,  NAKADA, Yoshihisa ,  MOCHIZUKI, Michiyo ,  FREEZE, Brian Scott ,  TAWARAISHI, Taisuke ,  WADA, Yasufumi ,  GREENSPAN, Paul D.

IPC: C07H21/00 ,  C07H21/02 ,  A61K31/7084 ,  A61P35/00

Abstract: The present disclosure provides a compound having a STING (stimulator of interferon genes) agonistic activity, which may be expected to be useful as an agent for the prophylaxis or treatment of STING-related diseases, such as cancer. The present disclosure relates to a compound represented by the formula (I) wherein each symbol is as defined in the description, or a salt thereof.

公开(公告)号：WO2018100558A3

公开(公告)日：2018-06-07

申请号：PCT/IB2017/057588

申请日：2017-12-01

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： YOSHIKAWA, Masato ,  SAITOH, Morihisa ,  KATO, Taisuke ,  YOSHITOMI, Yayoi ,  SEKI, Tomohiro ,  NAKAGAWA, Yasuo ,  TOMINARI, Yusuke ,  SETO, Masaki ,  SASAKI, Yusuke ,  OKANIWA, Masanori ,  ODA, Tsuneo ,  SHIBUYA, Akito ,  HIDAKA, Kosuke ,  SHIOKAWA, Zenyu ,  MURATA, Shumpei ,  OKABE, Atsutoshi ,  NAKADA, Yoshihisa ,  MOCHIZUKI, Michiyo ,  FREEZE, Brian Scott ,  TAWARAISHI, Taisuke ,  WADA, Yasufumi ,  GREENSPAN, Paul D.

IPC: C07H21/00 ,  C07H21/02 ,  A61K31/7084 ,  A61P35/00

Abstract: The present disclosure provides a compound having a STING (stimulator of interferon genes) agonistic activity, which may be expected to be useful as an agent for the prophylaxis or treatment of STING-related diseases, such as cancer. The present disclosure relates to a compound represented by the formula (I) wherein each symbol is as defined in the description, or a salt thereof.

公开(公告)号：WO2008082003A1

公开(公告)日：2008-07-10

申请号：PCT/JP2007/075427

申请日：2007-12-28

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED ,  ASO, Kazuyoshi ,  MOCHIZUKI, Michiyo ,  KOBAYASHI, Katsumi

Inventor： ASO, Kazuyoshi ,  MOCHIZUKI, Michiyo ,  KOBAYASHI, Katsumi

IPC: C07D235/14 ,  C07D235/08 ,  C07D235/10 ,  A61P25/24 ,  A61P25/22 ,  A61K31/4184

CPC classification number: C07D235/14 ,  C07D235/08 ,  C07D235/10

Abstract: There is provided a compound of the formula: wherein R 1 is an optionally substituted hydrocarbyl, a substituted amino, etc.; R 2 is an aromatic group substituted with one or two substituents at the positions adjacent to the position bonded to Z, and said aromatic group may have additional substituent(s); X is -NR 3 - wherein R 3 is a hydrogen, an optionally substituted hydrocarbyl or an acyl, or sulfur; Y 1 , Y 2 and Y 3 are an optionally substituted methine or a nitrogen, etc.; and Z is an optionally substituted methylene, provided that carbonyl is excluded; or a salt thereof or a prodrug thereof, which have CRF receptor antagonist activity and use thereof.

Abstract translation: 提供下式的化合物：其中R 1是任选取代的烃基，取代的氨基等; R 2是在与Z键合的位置相邻的位置上被一个或两个取代基取代的芳族基团，并且所述芳族基团可以具有另外的取代基; X是-NR 3 - ，其中R 3是氢，任选取代的烃基或酰基或硫; Y 1，Y 2和Y 3是任选取代的次甲基或氮等; 并且Z是任选取代的亚甲基，条件是不包括羰基; 或其盐或其前药，其具有CRF受体拮抗剂活性及其用途。